<!DOCTYPE html><html lang="en"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1"><title>Adrenergic and Cholinergic II - BHOLE</title><meta name="description" content="Direct Adrenergic Stimulants (agonists)Organization:Adrenergic Stimulants (Sympathomimetics)A1 Agonist:A2 Agonists:B1 and B2 agonist:B3 agonist:Direct Adrenergic Stimulants (agonists)Factors that influence response to cholinergic and adrenergic drugs:Physical chemical propertiesRoute of administration and the pharmacokinetic properiesLocalization density and proportion of receptorAffinity for receptor subtypesCompensatory reflexesReceptor desensitizationDisease StateAgeOrganization:Drugs acting on adrenergic&hellip;"><meta name="generator" content="Publii Open-Source CMS for Static Site"><link rel="canonical" href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html"><link rel="alternate" type="application/atom+xml" href="https://BGASM.github.io/medNotes/feed.xml"><link rel="alternate" type="application/json" href="https://BGASM.github.io/medNotes/feed.json"><meta property="og:title" content="Adrenergic and Cholinergic II"><meta property="og:site_name" content="BHOLE"><meta property="og:description" content="Direct Adrenergic Stimulants (agonists)Organization:Adrenergic Stimulants (Sympathomimetics)A1 Agonist:A2 Agonists:B1 and B2 agonist:B3 agonist:Direct Adrenergic Stimulants (agonists)Factors that influence response to cholinergic and adrenergic drugs:Physical chemical propertiesRoute of administration and the pharmacokinetic properiesLocalization density and proportion of receptorAffinity for receptor subtypesCompensatory reflexesReceptor desensitizationDisease StateAgeOrganization:Drugs acting on adrenergic&hellip;"><meta property="og:url" content="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html"><meta property="og:type" content="article"><link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin><link href="https://fonts.googleapis.com/css?family=Open+Sans:400,700|Roboto:400,700&amp;subset=latin-ext&amp;display=swap" rel="stylesheet"><style>:root{--body-font:'Open Sans',sans-serif;--heading-font:'Roboto',sans-serif;--logo-font:'Roboto',sans-serif;--menu-font:'Roboto',sans-serif}</style><link rel="stylesheet" href="https://BGASM.github.io/medNotes/assets/css/style.css?v=d2564d8d5f32cbb5488692bb93d80cc5"><script type="application/ld+json">{"@context":"http://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html"},"headline":"Adrenergic and Cholinergic II","datePublished":"2020-11-30T22:17","dateModified":"2020-12-06T17:04","description":"Direct Adrenergic Stimulants (agonists)Organization:Adrenergic Stimulants (Sympathomimetics)A1 Agonist:A2 Agonists:B1 and B2 agonist:B3 agonist:Direct Adrenergic Stimulants (agonists)Factors that influence response to cholinergic and adrenergic drugs:Physical chemical propertiesRoute of administration and the pharmacokinetic properiesLocalization density and proportion of receptorAffinity for receptor subtypesCompensatory reflexesReceptor desensitizationDisease StateAgeOrganization:Drugs acting on adrenergic&hellip;","author":{"@type":"Person","name":"William Slattery"},"publisher":{"@type":"Organization","name":"William Slattery"}}</script></head><body><div class="site-container"><header class="top" id="js-header"><a class="logo" href="https://BGASM.github.io/medNotes/">BHOLE</a><nav class="navbar js-navbar"><button class="navbar__toggle js-toggle" aria-label="Menu" aria-haspopup="true" aria-expanded="false"><span class="navbar__toggle-box"><span class="navbar__toggle-inner">Menu</span></span></button><ul class="navbar__menu"><li><a href="https://github.com/BGASM" target="_self">My Github</a></li><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Fall 2020</span><ul class="navbar__submenu level-2" aria-hidden="true"><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Pharmacology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html" target="_self">Adrenergic and Cholinergic I</a></li><li class="active"><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html" target="_self">Adrenergic and Cholinergic II</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html" target="_self">Adrenergic and Cholinergic III</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-inhibitors.html" target="_self">Adrenergic and Cholinergic IV</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html" target="_self">Adrenergic and Cholinergic V</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-i.html" target="_self">Chemotherapy I</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" target="_self">Chemotherapy II</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">Pathophysiology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" target="_self">Edema Congestion and Hemostasis</a></li><li><a href="https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html" target="_self">Hemorrhage Thrombosis and Embolism</a></li><li><a href="https://BGASM.github.io/medNotes/infarction-shock-and-dic.html" target="_self">Infarction Shock and DIC</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">MMG</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/virology-i.html" target="_self">Virology I</a></li><li><a href="https://BGASM.github.io/medNotes/virology-ii.html" target="_self">Virology II</a></li><li><a href="https://BGASM.github.io/medNotes/virology-iii.html" target="_self">Virology III</a></li><li><a href="https://BGASM.github.io/medNotes/virology-v.html" target="_self">Virology V</a></li><li><a href="https://BGASM.github.io/medNotes/virology-vii.html" target="_self">Virology VII</a></li></ul></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">NMS</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/02-principles-of-neurobiology.html" target="_self">Principles of Neurobiology I</a></li><li><a href="https://BGASM.github.io/medNotes/nms03-principles-of-neurobiology-ii.html" target="_self">Principles of Neurobiology II</a></li></ul></li><li><span class="is-separator">Peds</span></li></ul></nav></header><main><article class="post"><div class="hero"><figure class="hero__image hero__image--overlay"><img src="https://BGASM.github.io/medNotes/media/website/Jul24_GettyImages-582759294_neurons-scaled.jpg" srcset="https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xs.jpg 300w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-sm.jpg 480w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-md.jpg 768w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-lg.jpg 1024w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xl.jpg 1360w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-2xl.jpg 1600w" sizes="(max-width: 1600px) 100vw, 1600px" loading="eager" alt=""></figure><header class="hero__content"><div class="wrapper"><div class="post__meta"><time datetime="2020-11-30T22:17">November 30, 2020</time></div><h1>Adrenergic and Cholinergic II</h1><div class="post__meta post__meta--author"><a href="https://BGASM.github.io/medNotes/authors/william-slattery/" class="feed__author invert">William Slattery</a></div></div></header></div><div class="wrapper post__entry"><ul><li><a href="#-direct-adrenergic-stimulants-agonists">Direct Adrenergic Stimulants (agonists)</a></li><li><a href="#-organization">Organization:</a></li><li><a href="#-adrenergic-stimulants-sympathomimetics">Adrenergic Stimulants (Sympathomimetics)</a></li><li><a href="#---a1-agonists">A1 Agonist:</a></li><li><a href="#---a2-agonists">A2 Agonists:</a></li><li><a href="#---b1-and-b2-agonist">B1 and B2 agonist:</a></li><li><a href="#---b3-agonist">B3 agonist:</a></li></ul><h2 id="direct-adrenergic-stimulants-agonists">Direct Adrenergic Stimulants (agonists)</h2><hr><ul><li>Factors that influence response to cholinergic and adrenergic drugs:<ul><li>Physical chemical properties</li><li>Route of administration and the pharmacokinetic properies</li><li>Localization density and proportion of receptor</li><li>Affinity for receptor subtypes</li><li>Compensatory reflexes</li><li>Receptor desensitization</li><li>Disease State</li><li>Age</li></ul></li></ul><h2 id="organization">Organization:</h2><hr><ul><li>Drugs acting on adrenergic systems:</li><li>Peripheral (Sympathetic) and Central</li><li>Adrenergic stimulants: Mimetics<ul><li>Direct</li><li>Indirect</li><li>Both</li></ul></li><li>Adrenergic Blockers: Lytics<ul><li>Direct</li><li>Indirect<h2 id="adrenergic-stimulants-sympathomimetics">Adrenergic Stimulants (Sympathomimetics)</h2></li></ul></li></ul><hr><ul><li><p>Direct - Direct drugs mimic catecholamines as selective or non-selective. This is referring to therapeutic doses. In high concentration above the TD, drugs may lose selectivity.</p><ul><li><p>Adrenergic Receptor Agonists:</p><ul><li>Alpha 1 and 2</li><li>Beta 1, 2, 3</li><li>All coupled to G protein<ul><li>Metabotropic</li><li>Use of second messengers</li></ul></li></ul></li><li><h3 id="adrenergic-system-recap">Adrenergic System Recap:</h3><hr><ul><li>Sympathetic come from thoraco-lumbar region</li><li>Organized mainly in paravertebral ganglion</li><li>Pre-gang neuron uses ACh to communicate with post-gang neuron</li><li>Post-gang releases 80% NE, and only 20% Epi.</li><li>Fight or Flight<ul><li>Tachycardia, bronchodilation, vasoconstriction in most vessels</li><li>Vasodilation in SOME vessels, such as those supplying skeletal muscles</li></ul></li><li>Dopamine is released to control renal vascular tone, but not a primary catecholamine.</li><li>Adrenal gland acts as like a post-ganglion neuron.<ul><li>It releases 80% epinephrine, 20% NE &lt;&lt;&lt; Different than normal neurons.</li></ul></li><li>CNS is mostly affected by NE.<ul><li>Attention, alertness, concentration, energy, reduce appetite, sex drive.</li></ul></li></ul></li><li><h3 id="therapeutic-indication-of-ne">Therapeutic Indication of NE:</h3><hr><ul><li>Treat cardiogenic shock (IV)<ul><li>Increase total peripheral resistance.</li><li>Increase diastolic and systolic blood pressure during cardiogenic shock.</li><li>Poor oral bioavailability. Quikcly inactivated by COMT and MAO in the liver and gut.</li><li>Short action duration because it is matbolized.</li><li>Lack of selectivity.</li></ul></li></ul></li><li><h3 id="therapeutic-indications-of-epi">Therapeutic Indications of Epi:</h3><hr><ul><li>Rapid relief of anaphylaxis reactions</li><li>Prolong the effect of local anesthetics (alpha 1)</li></ul></li><li><p><strong>Ceases bleeding (hemostatic agent) (alpha1→ vasoconstriction)</strong></p></li><li><p>Beneficial for asthma</p><ul><li>B2: decrease in antigen-induced inflammatory mediator release</li><li>a1: decrease in bronchial secretion and congestion in mucosa</li><li><strong>B2: Increases bronchodilation</strong></li></ul></li><li><p>Adverse Effects:</p><ul><li>CNS: Anxiety and restlesness</li><li>PNS:<ul><li>Increase in physiological tremor (B2)</li><li>Palpitations (B1)</li><li>Increase blood sugar (A2)</li></ul></li></ul></li><li><h3 id="selectivity">Selectivity</h3></li></ul><hr><ul><li>Relative affinity: Epinephrine typically has a higher affinity for adrenergic receptors<ul><li>A1: Epi &gt; NE</li><li>A2: Epi &gt; NE</li><li>B1: NE= Epi</li><li>B2: Epi &gt;&gt;NE</li><li>B3: NE &gt; Epi</li></ul></li></ul><h2 id="a1-agonists">A1 Agonists:</h2><hr><ul><li><h3 id="phenylephrine">Phenylephrine:</h3><ul><li>Pharmacokinetics: within therapeutic doses it does not cross the BBB.<ul><li>Only metabolized by MAO. Not by COMPT. Higher Bioavail than epi.</li><li>Pharmacodynamics: Selective for A1-adrenergic agonist</li><li>Therapeutic Uses: are related with vasoconstriction<ul><li><strong>Nasal decongestant</strong></li><li>Maintain BP during anesthesia</li><li>Cause contraction in radial muscle</li><li>Contraction in pupils - Mydriassis</li></ul></li><li>Adverse Effects:<ul><li>Excess vasoconstriction</li><li>Insomnia</li><li><strong>Rebound nasal congestion</strong><ul><li>After three days the therapeutic affect drops, and congestion rebounds severely.</li></ul></li><li>May worsen prostatic hyperplasia</li><li>Urinary bladder sphincter contraction</li><li>Drug interactions:<ul><li>MAO inhibitor will prolong</li></ul></li><li><strong>Potential Systemic Problems:</strong><ul><li>associated to BP, like hypertension and <strong>reflex bradycardia</strong></li><li>BP = CO * TPR</li><li>High % A1 receptors in these vessels.</li><li>Agonist causes vascular contraction, which increases BP.</li><li>To react to the increased BP, CO decreases, causing bradycardia.</li></ul></li></ul></li></ul></li></ul></li><li><h3 id="midodrine">Midodrine:</h3><ul><li>Therapeutic Use related with Vasoconstriction<ul><li><strong>Orthostatic hypotension</strong></li></ul></li><li>Adverse Effects due to A1 Stimulation<ul><li>Vasoconstriction = hypertension</li><li><strong>Contraction in urinary bladder sphincter = Urinary retention</strong></li></ul></li></ul></li></ul></li><li><h2 id="a2-agonists">A2 Agonists:</h2><hr><pre><code>  - Coupled to Gi proteins, which are inhibitory
  - Decrease in NT release
  - Decrease insulin secretion from Pancreatic B cells.
  - Decreased sympathetic nerve activity due to brainstem (CNS) adrenoreceptors
  - Increase aqueous outflow of humor in the eyes.</code></pre><ul><li><h3 id="clonidine-central-acting-adrenergic-agonist">Clonidine: Central Acting Adrenergic Agonist</h3><ul><li>Good bioavailability and crosses BBB, reaching the A2 receptors in the brainstem.</li><li><strong>Reduce Adrenergic discharge of norepinephrine</strong></li><li>Therapeutic Uses:<ul><li><strong>Reduce Hypertension</strong>, withdrawal symptoms.</li></ul></li><li>Adverse Effects:<ul><li>Dry mouth, fatigue</li><li><strong>Orthostatic Hypotension (old patients may fall)</strong></li></ul></li></ul></li><li><h3 id="apraclonidine-and-brimonidine">Apraclonidine and Brimonidine:</h3><ul><li>Topical Intraocular administration</li><li>Treat decrease pressure caused accumulation of aqueous outflow.</li><li>Therapeutic Use:<ul><li>Open-angle glaucome</li></ul></li><li>Adverse Effect:<ul><li>Orthostatic hypotension caused if drug reaches systemic circulation</li></ul></li></ul></li><li><h3 id="methyldopa">Methyldopa:</h3><ul><li>Prodrug. Distribution throughout the body (placenta, BBB)</li><li>CNS mainly. Causes a reduction in the release of NE from CNS</li><li>Decrease sympathetic tone, which decreases total peripheral resistance.</li><li>Therapeutic Use:<ul><li>Decrease hypertension</li><li><strong>Drug of choice for hypertension during pregnancy and breastfeeding</strong></li><li></li></ul></li></ul></li></ul></li><li><h2 id="b-1-adrenergic-receptor-agonist">B-1 Adrenergic Receptor Agonist:</h2></li></ul><hr><pre><code>  - Increased Heart Rate: Positive chronotropic effect
  - Increase force: Positive inotropic effect
  - Increase automaticity: Positive dromotropic effect
  - Increased Cardiac Output:
  - Dobutamine, Dopamine (mostly cardio-stimulatory effects)</code></pre><ul><li><h3 id="dopamine">Dopamine</h3><ul><li>PK: Very short acting (substrate for transporters and enzymes)</li><li>Dose dependent.</li><li>Therapeutic EffecT: Moderate Dose<ul><li>Severe congestive heart failure</li><li>Cardiogenic shock with hypotension</li></ul></li><li>Low Dose:<ul><li><strong>Increase renal blood floow. DA1 agonist in kidneys</strong></li><li>Cause vomiting D2 in CNS.</li></ul></li><li>High Dose:<ul><li>A1 agonist. Increases peripheral vascular resistance: cardiac output, heart rate</li></ul></li></ul></li><li><h3 id="dobutamine">Dobutamine:</h3><ul><li>PK: Short duration, IV adm.</li><li>Only stimulate B1 receptors</li><li>Positive inotropic drug</li><li>Small amount of vasoconstriction due to A1-agonism</li><li>Therapeutic:<ul><li>Drug of choice to treat cardiogenic shock</li></ul></li><li>Does not cause vomiting or increase renal blood flow.</li><li>Can cause tachycardia.<ul><li><h2 id="b-2-adrenergic-receptor-agonist">B-2 Adrenergic Receptor Agonist:</h2></li></ul></li></ul></li></ul><hr><pre><code>  - Smooth muscle relaxation
  - Some blood vessels: vasodilation
      - Skeletal, liver, heart, coronary
  - Glycogenolysis, gluconeogenesis
  - Increase insulin release from pancreas.
  - Mast cells decrease histamine release.
  - Adrenergic neurons increase NE release.</code></pre><ul><li><strong>SABA - Short Acting Beta Agonist</strong><pre><code> - Abuterol, Terbutaline - SABA
 - Fast onset and offset.</code></pre></li><li><strong>LABA - Long Acting Beta Agonist</strong><pre><code> - Formoterol - fast onset
 - Salmeterol - slow onset</code></pre><ul><li>Effect of B2 activation<ul><li>Bronchorelaxation</li><li>Reduction of airway inflammation</li><li>Reduction of episodic bronchospasms due to allergens</li></ul></li><li>Therapeutic Use: Asthma and COPD<ul><li><strong>Terbutaline is used as off-label to delay premature labor.</strong></li></ul></li><li>Adverse Effect:<ul><li>Tremor</li><li>Tachycardia</li><li><strong>Insulin secretion. - Terbutaline</strong><ul><li><h2 id="b1-and-b2-agonist">B1 and B2 agonist:</h2></li></ul></li></ul></li></ul></li></ul><hr><ul><li><h3 id="isoproterenol">Isoproterenol:</h3><ul><li>Target organs:<ul><li>Heart - B1</li><li>Lungs - B2</li></ul></li><li>PK: Metabolized by liver (COMT): brief duration of action</li><li>Effects:<ul><li>Stimulate heart (B1)</li><li>Vasodilator - vessels that irrigate skeletal muscle(B2)</li><li>Bronchodilation (B2)</li></ul></li><li>Therapeutic:<ul><li>Rarely used</li><li>Heart block to stimulate heart B1 and management is asthma/bronchitis B2</li></ul></li><li>Adverse effect: Tachycardia, headache, flushing</li><li><h2 id="b3-agonist">B3 agonist:</h2></li></ul></li></ul><hr><ul><li><h3 id="mirabegron">Mirabegron</h3><ul><li>Affect:<ul><li>Endogenous B3 Agonist Activate lipolysis in fat cells.</li><li><strong>The Mirabegron drug does NOT have the effect.</strong></li><li><strong>Detrusor muscle relaxation</strong> in smooth muslce tissue of the urinary bladder</li></ul></li><li>B3 receptor in detrusor muscle in bladder. Couple to Gi protein, so has inhibitory affect, which relaxes the muscle. It allows storage of more urine.</li><li>Therapeutic:<ul><li>Treat symptoms of frequent or urgent urination and incontinence due to overactive bladder (OAB).</li></ul></li><li>PK: Good bioavailabilty, no BBB crossing</li><li>AE: <strong>Urinary</strong> retention, Tachycardia, Tremor</li><li>Non-Selective</li></ul></li></ul></div><footer class="wrapper post__footer"><p class="post__last-updated">This article was updated on December 6, 2020</p></footer></article><nav class="post__nav"><div class="post__nav-inner"><div class="post__nav-prev"><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-prev"/></svg> <a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" class="invert post__nav-link" rel="prev"><span>Previous</span> PSL I Edema Congestion and Hemostasis</a></div><div class="post__nav-next"><a href="https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html" class="invert post__nav-link" rel="next"><span>Next</span> PSL II Hemorrhage Thrombosis and Embolism </a><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-next"/></svg></div></div></nav></main><footer class="footer"><div class="footer__copyright"><p>Powered by <a href="https://getpublii.com" target="_blank" rel="nofollow noopener">Publii</a></p></div><button class="footer__bttop js-footer__bttop" aria-label="Back to top"><svg><title>Back to top</title><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#toparrow"/></svg></button></footer></div><script>window.publiiThemeMenuConfig = {    
        mobileMenuMode: 'overlay',
        animationSpeed: 300,
        submenuWidth: 'auto',
        doubleClickTime: 500,
        mobileMenuExpandableSubmenus: true, 
        relatedContainerForOverlayMenuSelector: '.top',
   };</script><script defer="defer" src="https://BGASM.github.io/medNotes/assets/js/scripts.min.js?v=f4c4d35432d0e17d212f2fae4e0f8247"></script><script>var images = document.querySelectorAll('img[loading]');

        for (var i = 0; i < images.length; i++) {
            if (images[i].complete) {
                images[i].classList.add('is-loaded');
            } else {
                images[i].addEventListener('load', function () {
                    this.classList.add('is-loaded');
                }, false);
            }
        }</script></body></html>